Your last SELECT statement was:
S FRANCISELLA (1W) TULARENSIS

Ref	Items	File
N51	9	649: Gale Group Newswire ASAP(TM)_2006/Sep 18
N52	8	74: Int.Pharm.Abs_1970-2006/Aug B2
N53	8	229: Drug Info. Fulltext_2002
N54	7	68: Solid State & Superconductivity Abstracts_1966-200
N55	7	393: Beilstein Abstracts_2006/Q3
N56	7	613: PR Newswire_1999-2006/Oct 02
N57	6	9: Business & Industry(R)_Jul/1994-2006/Sep 29
N58	6	104: AeroBase_1999-2006/Aug
N59	6	167: Medical Device Register (R)_1999
N60	6	345: Inpadoc/Fam.& Legal Stat_1968-2006/UD=200639

122 files have one or more items; file list includes 297 files.

- Enter P or PAGE for more -

```
? b n1-n60;exs
       02oct06 10:57:23 User228210 Session D414.3
            $3.68    1.388 DialUnits File411
     $3.68  Estimated cost File411
     $0.53  TELNET
     $4.21  Estimated cost this search
     $4.23  Estimated total session cost   1.708 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 398:Chemsearch 1957-2006/Sep
         (c) 2006 Amer.Chem.Society
*File 398: Use is subject to the terms of your user/customer agreement.
Problems with SORT.  RANK charge added. See HELP RATES 398.
  File 155:MEDLINE(R) 1950-2006/Oct 02
         (c) format only 2006 Dialog
  File   5:Biosis Previews(R) 1969-2006/Sep W4
         (c) 2006 The Thomson Corporation
  File  73:EMBASE 1974-2006/Oct 02
         (c) 2006 Elsevier B.V.
  File 162:Global Health 1983-2006/Aug
         (c) 2006 CAB International
  File 440:Current Contents Search(R) 1990-2006/Oct 02
         (c) 2006 The Thomson Corp
  File  50:CAB Abstracts 1972-2006/Aug
         (c) 2006 CAB International
  File 399:CA SEARCH(R) 1967-2006/UD=14514
         (c) 2006 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.
  File  34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W4
         (c) 2006 The Thomson Corp
  File 654:US Pat.Full. 1976-2006/Sep 28
         (c) Format only 2006 Dialog
*File 654: IPCR/8 classification codes now searchable in 2006 records.
For information about IC= index changes, see HELP NEWSIPCR.
  File 349:PCT FULLTEXT 1979-2006/UB=20060928UT=20060921
         (c) 2006 WIPO/Thomson
*File 349: For important information about IPCR/8 and forthcoming
changes to the IC= index, see HELP NEWSIPCR.
  File 144:Pascal 1973-2006/Sep W2
         (c) 2006 INIST/CNRS
  File  24:CSA Life Sciences Abstracts 1966-2006/Aug
         (c) 2006 CSA.
  File  71:ELSEVIER BIOBASE 1994-2006/Oct W1
         (c) 2006 Elsevier B.V.
```

File 156:ToxFile 1965-2006/Sep W4
(c) format only 2006 Dialog
File 149:TGG Health&Wellness DB(SM) 1976-2006/Sep W2
(c) 2006 The Gale Group
File 10:AGRICOLA 70-2006/Aug
(c) format only 2006 Dialog
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 2006 The Thomson Corp
File 266:FEDRIP 2006/Aug
Comp & dist by NTIS, Intl Copyright All Rights Res
File 6:NTIS 1964-2006/Sep W4
(c) 2006 NTIS, Intl Cpyrght All Rights Res
File 45:EMCare 2006/Sep W4
(c) 2006 Elsevier B.V.
File 185:Zoological Record Online(R) 1978-2006/Oct
(c) 2006 The Thomson Corp.
File 340:CLAIMS(R)/US Patent 1950-06/Sep 28
(c) 2006 IFI/CLAIMS(R)
*File 340: IPCR/8 classification codes now searchable in 2006 records.
For important information about IC=index changes, see HELP NEWSIPCR.
File 135:NewsRx Weekly Reports 1995-2006/Sep W4
(c) 2006 NewsRx
File 357:Derwent Biotech Res. _1982-2006/Sep W4
(c) 2006 The Thomson Corp.
File 484:Periodical Abs Plustext 1986-2006/Sep W4
(c) 2006 ProQuest
File 180:Federal Register 1985-2006/Sep 28
(c) 2006 format only DIALOG
File 348:EUROPEAN PATENTS 1978-2006/ 200638
(c) 2006 European Patent Office
*File 348: For important information about IPCR/8 and forthcoming
changes to the IC= index, see HELP NEWSIPCR.
File 148:Gale Group Trade & Industry DB 1976-2006/Oct 02
(c)2006 The Gale Group
File 203:AGRIS 1974-2006/Jul
Dist by NAL, Intl Copr. All rights reserved
File 444:New England Journal of Med. 1985-2006/Sep W3
(c) 2006 Mass. Med. Society
File 16:Gale Group PROMT(R) 1990-2006/Sep 29
(c) 2006 The Gale Group
File 20:Dialog Global Reporter 1997-2006/Oct 02
(c) 2006 Dialog
File 143:Biol. & Agric. Index 1983-2006/Jul
(c) 2006 The HW Wilson Co
File 8:Ei Compendex(R) 1970-2006/Sep W4
(c) 2006 Elsevier English Info. Inc.
File 94:JICST-EPlus 1985-2006/Jun W4
(c)2006 Japan Science and Tech Corp(JST)
File 98:General Sci Abs 1984-2006/Sep
(c) 2006 The HW Wilson Co.
File 390:Beilstein Facts 2006/Q3
(c) 2006 Beilstein GmbH
*File 390: File has been reloaded. Please see HELP NEWS 390.
IMPORTANT - Price based on output. See HELP RATES 390.
File 65:Inside Conferences 1993-2006/Oct 02
(c) 2006 BLDSC all rts. reserv.
File 292:GEOBASE(TM) 1980-2006/Sep W2
(c) 2006 Elsevier B.V.
File 35:Dissertation Abs Online 1861-2006/Sep
(c) 2006 ProQuest Info&Learning
File 636:Gale Group Newsletter DB(TM) 1987-2006/Sep 29
(c) 2006 The Gale Group
File 47:Gale Group Magazine DB(TM) 1959-2006/Sep 29
(c) 2006 The Gale group

```
  File 305:Analytical Abstracts 1980-2006/Sep W2
        (c) 2006 Royal Soc Chemistry
*File 305: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling.  See HELP ALERT.
  File 172:EMBASE Alert 2006/Oct 02
        (c) 2006 Elsevier B.V.
  File 355:Derwent Chemistry Resource UD=200661
        (c) 2006 The Thomson Corporation
  File 136:BioEngineering Abstracts 1966-2006/Aug
        (c) 2006 CSA.
  File   2:INSPEC 1898-2006/Sep W3
        (c) 2006 Institution of Electrical Engineers
  File 324:German Patents Fulltext 1967-200638
        (c) 2006 Univentio
*File 324: For important information about IPCR/8 and forthcoming
changes to the IC= index, see HELP NEWS IPCR.
  File 621:Gale Group New Prod.Annou.(R) 1985-2006/Sep 29
        (c) 2006 The Gale Group
  File 649:Gale Group Newswire ASAP(TM) 2006/Sep 18
        (c) 2006 The Gale Group
  File  74:Int.Pharm.Abs 1970-2006/Aug B2
        (c) 2006 The Thomson Corporation
  File 229:Drug Info. Fulltext 2002
        (c) 2002 Ameri.Soc.of Health-Systems Pharm.
  File  68:Solid State & Superconductivity Abstracts 1966-2006/Sep
        (c) 2006 CSA.
  File 393:Beilstein Abstracts 2006/Q3
        (c) 2006 Beilstein GmbH
  File 613:PR Newswire 1999-2006/Oct 02
        (c) 2006 PR Newswire Association Inc
*File 613: File 613 now contains data from 5/99 forward.
Archive data (1987-4/99) is available in File 813.
  File   9:Business & Industry(R) Jul/1994-2006/Sep 29
        (c) 2006  The Gale Group
  File 104:AeroBase 1999-2006/Aug
        (c) 2006 Contains copyrighted material
  File 167:Medical Device Register (R) 1999
        (c) 2006 The Thomson Corporation
*File 167: This file is closed (no updates)
  File 345:Inpadoc/Fam.& Legal Stat 1968-2006/UD=200639
        (c) 2006 EPO
*File 345: IPCR/8 classification codes now searchable in 2006 records.
For important information about IC= index changes, see HELP NEWSIPCR.

      Set  Items  Description
      ---  -----  -----------
Executing TF30565077
Hilight option is not available in file(s) 398, 399
HILIGHT set on as '%'
          15695  FRANCISELLA
          15492  TULARENSIS
      S1  13995  FRANCISELLA (1W) TULARENSIS
```

```
Set     Items   Description
S1      13995   FRANCISELLA (1W) TULARENSIS
S2       3937   S1 AND PROTEIN
S3         21   S2 AND 52 (1W) KDA
S4         20   RD  (unique items)
? s s2 and 52 (1w) kilodalton?
Processed  50 of  60 files ...
Completed processing all files
           3937  S2
        8444713  52
         102296  KILODALTON?
           1162  52(1W)KILODALTON?
     S5       2  S2 AND 52 (1W) KILODALTON?
? t s5/3,ab/1-2
>>>No matching display code(s) found in file(s): 65, 135, 167, 180, 229,
   345, 355, 390, 398

 5/3,AB/1     (Item 1 from file: 156)
DIALOG(R)File 156:ToxFile
(c) format only 2006 Dialog. All rts. reserv.

232066   NLM Doc No: NTIS/01920051   Sec. Source ID: NTIS/ADA433381
    %52%   %Kilodalton%   %Protein%  Vaccine  Candidate  for  %Francisella%
%tularensis%.
  Sikora CA; Berger BJ; Cherwonogrodsky JW
  DEFENCE RESEARCH AND DEVELOPMENT SUFFIELD (ALBERTA).
  Source: Govt Reports Announcements & Index (GRA&I), Issue 19, 2005
  Pub. Year: 2004
  Order  Information: 40p Product reproduced from digital image. Order this
product  from  NTIS  by:  phone  at  1-800-553-NTIS  (U.S.  customers);
(703)605-6000  (other  countries);  fax  at  (703)605-6900;  and  email  at
orders@ntis.gov.  NTIS is located at 5285 Port Royal Road, Springfield, VA,
22161, USA.
  NTIS Prices: PC A04/MF A01
  Languages: UNSPECIFIED
  Record type: Completed
  Technical  memorandum. For identifying %Francisella% %tularensis% vaccine
candidates,  mice  were  first  vaccinated  with  Brucella  abortus
O-polysaccharide  (OPS)  vaccine.  These  animals were then given 10 LD(sub
50S) of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the
vaccinated  mice  survived  the  multiple  lethal  dose  while  all  the
unvaccinated  control  mice  perished.  Sera  were  collected  from  these
surviving  mice  and  used to probe supernatant and cell lysates of live F.
tularensis LVS cultures. Several %Francisella% %tularensis% components were
identified  by  this noted antiserum. Mouse serum from mice vaccinated with
killed F. tularensis did not identify these components. Of these identified
proteins,  enzyme  digestions  and  chemical  oxidation  suggest
post-translational modifications for some of the proteins (e.g. a %52%
%kilodalton% (kDa) glycoprotein, a 45 kDa lipoprotein and a 19 kDa
nucleoprotein).  In low concentrations, the 52 kDa component caused nitrous
oxide  induction  in  tissue  cultures and in high concentrations it caused
cell  death.  Vaccination  with this %protein% gave mice partial protection
(20%  survival)  from  250 LD(sub 50) of tularemia given intranasally while
the  addition  of  other  components may have acted synergistically to give
enhanced protection (i.e. 100% survival).


 5/3,AB/2     (Item 1 from file: 6)
DIALOG(R)File   6:NTIS
(c) 2006 NTIS, Intl Cpyrght All Rights Res. All rts. reserv.

2320218  NTIS Accession Number: ADA433381/XAB
    %52%   %Kilodalton%   %Protein%  Vaccine  Candidate  for  %Francisella%
%tularensis%
```

applicab

(Technical memorandum)
Sikora, C. A. ; Berger, B. J. ; Cherwonogrodsky, J. W.
DEFENCE RESEARCH AND DEVELOPMENT SUFFIELD (ALBERTA).
Corp. Source Codes: 888888888; 441804
Report Number: DRDC-S-TM-2004-074
Dec 2004 40p
Languages: English
Journal Announcement: USGRDR0519

Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

NTIS Prices: PC A04/MF A01

For identifying %Francisella% %tularensis% vaccine candidates, mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD(sub 50S) of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal dose while all the unvaccinated control mice perished. Sera were collected from these surviving mice and used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several %Francisella% %tularensis% components were identified by this noted antiserum. Mouse serum from mice vaccinated with killed F. tularensis did not identify these components. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications for some of the proteins (e.g. a %52% %kilodalton% (kDa) glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein). In low concentrations, the 52 kDa component caused nitrous oxide induction in tissue cultures and in high concentrations it caused cell death. Vaccination with this %protein% gave mice partial protection (20% survival) from 250 LD(sub 50) of tularemia given intranasally while the addition of other components may have acted synergistically to give enhanced protection (i.e. 100% survival).
?

? ds

Set	Items	Description
S1	13995	FRANCISELLA (1W) TULARENSIS
S2	3937	S1 AND PROTEIN
S3	21	S2 AND 52 (1W) KDA
S4	20	RD (unique items)

? t s4/3,ab/1-20
>>>No matching display code(s) found in file(s): 65, 135, 167, 180, 229, 345, 355, 390, 398

4/3,AB/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

141156100 CA: 141(10)156100y PATENT
Mammals immunizing sequentially with different infectious agents and observing cross-protection to identify novel vaccine candidates
INVENTOR(AUTHOR): Sikora, Christopher A.; Berger, Bradley J.; Cherwonogrodzky, John W.
LOCATION: Can.,
PATENT: U.S. Pat. Appl. Publ. ; US 20040151736 A1 DATE: 20040805
APPLICATION: US 762241 (20040123) *US PV442072 (20030124)
PAGES: 21 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424190100; A61K-039/02A

4/3,AB/2 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.

6742770
UTILITY
Masp-2, a complement-fixing enzyme, and uses for it
Inventor: Jensenius, Jens Christian, Finsens Alle 28, DK-52, Odense M, DK
Thiel, Steffen, Nordtoftevej 11, DK-82, Risskov, DK
Assignee: Unassigned
Examiner: Nashed, Nashaat T.
Assistant Examiner: Moore, William W.
Legal Representative: Cooper, Iver P.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 7112414	B2	20060926	US 2001332713	20010713
Related Publ	US 20040038297	A1	20040226		
PCT	WO 200206460	A	20020124	WO 2001DK499	20010713

US Term Extension: 11 days

Fulltext Word Count: 20913
Abstract:
[00000] The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and/or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are

included in the invention.

4/3,AB/3 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.

6739280
UTILITY
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
Inventor: Roy, Soumitra, Wayne, PA, US
Wilson, James M., Gladwyne, PA, US
Assignee: The Trustees of the University of Pennsylvania, (02), 3160 Chestnut Street, Suite 200, Philadelphia, 19104-6283, PA
Correspondence Address: HOWSON AND HOWSON, SUITE 210, 501 OFFICE CENTER DRIVE, FT WASHINGTON, PA, 19034, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060211115	A1	20060921	US 2004561201	20040615
PCT	WO 2004US16614		20040615		
Provisional				US 60-566212	20040428
Provisional				US 60-575429	20040528
Priority				US 20031046530	20030620

Fulltext Word Count: 23119

Abstract:
[00000] A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the (5') inverted terminal repeat, the left terminus spans the E4 region and the (3') inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.

4/3,AB/4 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.

6403420
Derwent Accession: 2006-108970
UTILITY
Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
Inventor: Georges, Elias, Laval, CA
Serfass, Lucile, Montreal, CA
Bonneau, Anne-Marie, Laval, CA
Dallaire, Frederic, Montreal, CA
Assignee: Aurelium BioPharma Inc., (03)
Correspondence Address: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US

	Publication Number	Kind	Date	Application Number	Filing Date

Main Patent	US 20060014225	A1	20060119	US 2005173672	20050701
Division	PENDING			US 2003736889	20031215
Provisional				US 60-433480	20021213

Fulltext Word Count: 51392

Abstract:
[00000] Disclosed are methods for treating or preventing a neoplastic or a multidrug resistant neoplasm in a subject using cell surface vimentin targeted therapeutic.

4/3,AB/5 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5976089
Derwent Accession: 2004-668914
UTILITY
Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
Inventor: Georges, Elias, Laval, CA
Serfass, Lucile, Montreal, CA
Bonneau, Anne-Marie, Laval, CA
Dallaire, Frederic, Montreal, CA
Assignee: Aurelium BioPharma, Inc., (03)
Correspondence Address: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20050026231	A1	20050203	US 2004801988	20040315
Provisional				US 60-455005	20030314

Fulltext Word Count: 47339

Abstract:
[00000] Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) %protein% in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase %protein% in a normal cell.

4/3,AB/6 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5950031
Derwent Accession: 2004-525100
UTILITY
Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
Inventor: Georges, Elias, Laval, CA
Serfass, Lucile, Montreal, CA
Bonneau, Anne-Marie, Laval, CA
Dallaire, Frederic, Montreal, CA
Assignee: Aurelium BioPharma, Inc., (03)
Correspondence Address: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20050009119	A1	20050113	US 2003737712	20031215
Provisional				US 60-433351	20021213

Fulltext Word Count: 54254

Abstract:
[00000] Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a nucleophosmin (NPM) protein on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the nucleophosmin protein on the surface of a normal cell.

4/3,AB/7 (Item 6 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005922328
Derwent Accession: 2005-078943
Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
Inventor: Georges, Elias, INV
Serfass, Lucile, INV
Bonneau, Anne-Marie, INV
Dallaire, Frederic, INV
Assignee: Aurelium BioPharma Inc.(03)
Correspondence Address: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040259112	A1	20041223	US 2003736889	20031215
Provisional				US 60-433480	20021213

Fulltext Word Count: 58100
Abstract:
Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin %protein% in such cells as compared to the level of cell surface expression of vimentin %protein% in a normal cell or a non-MDR neoplastic cell.

4/3,AB/8 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005806430
Derwent Accession: 2004-553396
HSC70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
Inventor: Georges, Elias, INV
Serfass, Lucile, INV
Bonneau, Anne-Marie, INV

Dallaire, Frederic, INV
Assignee: Aurelium BioPharma, Inc.(03)
Correspondence Address: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040185511	A1	20040923	US 2003737350	20031215
Provisional				US 60-438012	20030103

Fulltext Word Count: 57598

Abstract:
Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) %protein% 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 %protein% on the surface of a normal cell.

4/3,AB/9 (Item 8 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005746588
Derwent Accession: 2004-570708
Use of cross-protection to identify novel vaccine candidates for infectious agents
Inventor: Sikora, Christopher, INV
Berger, Bradley, INV
Cherwonogrodzky, John, INV
Correspondence Address: NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD 8TH FLOOR, ARLINGTON, VA, 22201-4714, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040151736	A1	20040805	US 2004762241	20040123
Provisional				US 60-442072	20030124

applicant

Fulltext Word Count: 11625

Abstract:
This invention discloses methods for identifying %Francisella% %tularensis% vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD[sub]50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted "survivor" antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a %52% %kDa% %glycoprotein%, a 45 kDa %lipoprotein% and a 19 kDa %nucleoprotein%. The %52% %kDa% component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high

concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD[sub]50s of F. tularensis LVS.

4/3,AB/10 (Item 9 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005551620
Derwent Accession: 2002-179791
Masp-2,a complement-fixing enzyme, and uses for it
Inventor: Jensenius, Jens, INV
Thiel, Steffen, INV
Correspondence Address: BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040038297	A1	20040226	US 2003332713	20030703
PCT					
Priority				DK 20001089	20000713
				DK 2001870	20010601

Fulltext Word Count: 26386

Abstract:
The present invention relates to substantially pure mannin-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Futhermone, the present invention realates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositons comprising MASP-2 and/or MASP-2 fragments. In addition the present invetion relates to inhibitors of MASP-2 and pharmaceutical compositiosn compring such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.

4/3,AB/11 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01253755
VIMENTIN DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE
DIAGNOSTIC DIRIGE SUR LA VIMENTINE ET METHODE THERAPEUTIQUE POUR MALADIES NEOPLASIQUES A MULTIRESISTANCE AUX MEDICAMENTS
Patent Applicant/Assignee:
AURELIUM BIOPHARMA INC, 8475 Christophe-Colomb Avenue, Suite 1000, Montreal, Quebec City H2M 2N9, CA, CA (Residence), CA (Nationality)
Inventor(s):
GEORGES Elias, 2095 de Vouvray, Laval, Quebec H7M 3J7, CA,
SERFASS Lucile, 5291 de l'Esplanade, Montreal, Quebec H2T 2Z6, CA,
BONNEAU Anne-Marie, 2095 De Vouvray, Laval, Quebec H7M 3J7, CA,
DALLAIRE Frederic, 4683 Mentana, Montreal, Quebec H2J 3B7, CA,
Legal Representative:

OGILVY RENAULT (agent), Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200562058 A1 20050707 (WO 0562058)
Application: WO 2003IB6427 20031215 (PCT/WO IB03006427)
Priority Application: WO 2003IB6427 20031215
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 53444

English Abstract
Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin %protein% in such cells as compared to the level of cell surface expression of vimentin %protein% in a normal cell or a non-MDR neoplastic cell.

French Abstract
Ces methodes permettent de detecter la multiresistance aux medicaments dans des cellules neoplasiques ou endommagees ou de detecter des cellules neoplasiques ou endommagees a multiresistance aux medicaments par detection d'une augmentation de l'expression de la proteine vimentine dans la surface de la cellule par rapport a l'expression de la proteine vimentine dans la surface d'une cellule normale ou neoplasique n'ayant pas une multiresistance aux medicaments.

4/3,AB/12 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01194985
METHODS OF GENERATING CHIMERIC ADENOVIRUSES AND USES FOR SUCH CHIMERIC ADENOVIRUSES
PROCEDE POUR PRODUIRE DES ADENOVIRUS CHIMERIQUES ET UTILISATIONS DE CES DERNIERS
Patent Applicant/Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
ROY Soumitra, 240 Pugh Road, Wayne, PA 19087, US, US (Residence), US (Nationality), (Designated only for: US)
WILSON James M, 1350 N. Avignon Drive, Gladwyne, PA 19035, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
KODROFF Cathy A (et al) (agent), Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200501103 A2-A3 20050106 (WO 0501103)
Application: WO 2004US16614 20040615 (PCT/WO US04016614)

Priority Application: US 2003465302 20030620; US 2004566212 20040428; US 2004575429 20040528
Parent Application/Grant:
Related by Continuation to: US 2003465302 20030620 (CIP)
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 22543

English Abstract
A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the (5') inverted terminal repeat, the left terminus spans the E4 region and the (3') inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.

French Abstract
L'invention concerne un procede pour obtenir un adenovirus, a partir d'un serotype qui ne croit pas de maniere efficace dans une lignee cellulaire desiree, presentant la capacite de croitre dans cette lignee cellulaire. Ledit procede consiste a remplacer les extremites gauche et droite de l'adenovirus par les extremites correspondantes d'un adenovirus qui croit de maniere efficace dans la lignee cellulaire desiree. Au minimum, l'extremite gauche couvre la repetition terminale inversee en (5'), l'extremite gauche couvre la region E4 et la repetition terminale inversee en (3'). L'adenovirus chimerique ainsi obtenu contient des regions internes couvrant les genes codant le pentone, l'hexone et la fibre obtenues a partir du serotype qui ne croit pas efficacement dans la cellule desiree. L'invention concerne egalement des vecteurs construits a partir de nouvelles sequences et proteines d'adenovirus simien, des cellules hotes les contenant ainsi que leurs utilisations.

4/3,AB/13 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01158909
TRIOSEPHOSPHATE ISOMERASE DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE
METHODE DE DIAGNOSTIC ET DE THERAPIE CIBLANT LA TRIOSE-PHOSPHATE ISOMERASE, DESTINEE AUX MALADIES NEOPLASIQUES A MULTIRESISTANCE AUX MEDICAMENTS
Patent Applicant/Assignee:
AURELIUM BIOPHARMA INC, 8475 Christophe-Colomb Avenue, Suite 1000, Montreal, Quebec City H2M 2N9, CA, CA (Residence), CA (Nationality)
Inventor(s):

GEORGES Elias, 2095 de Vouvray, Laval, Quebec H7M 3J7, CA,
SERFASS Lucile, 5291 de l'Esplanade, Montreal, Quebec H2T 2Z6, CA,
BONNEAU Anne-Marie, 2095 De Vouvray, Laval, Quebec H7M 3J7, CA,
DALLAIRE Frederic, 4683 Mentana, Montreal, Quebec H2J 3B7, CA,
Legal Representative:
OGILVY RENAULT (agent), Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200480819 A2-A3 20040923 (WO 0480819)
Application: WO 2004IB1240 20040315 (PCT/WO IB04001240)
Priority Application: US 2003455005 20030314
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 45338

English Abstract
Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) %protein% in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase %protein% in a normal cell.

French Abstract
Procedes de detection de cellules neoplasiques ou endommagees ainsi que de la multiresistance aux medicaments dans des cellules neoplasiques ou endommagees, consistant a detecter une augmentation de l'expression cellulaire d'une proteine triose-phosphate isomerase (TPI) dans des cellules neoplasiques ou endommagees a multiresistance aux medicaments, par rapport au niveau d'expression de ladite proteine dans une cellule normale.

4/3,AB/14 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01138508
HSC70 DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE
PROCEDES DIAGNOSTIQUES ET THERAPEUTIQUES DIRIGES PAR HSC70 POUR LES MALADIES NOEPLASIQUES RESISTANT A DE MULTIPLES MEDICAMENTS
Patent Applicant/Assignee:
AURELIUM BIOPHARMA INC, 8475 Christophe-Colomb Avenue, Suite 1000, Montreal, Quebec City H2M 2N9, CA, CA (Residence), CA (Nationality), (Designated for all)
Inventor(s):
GEORGES Elias, 2095 de Vouvray, Laval, Quebec H7M 3J7, CA, (Designated for all)
SERFASS Lucile, 5291 de l'Esplanade, Montreal, Quebec H2T 2Z6, CA, (Designated for all)
BONNEAU Anne-Marie, 2095 De Vouvray, Laval, Quebec H7M 3J7, CA,

(Designated for all)
DALLAIRE Frederic, 4683 Mentana, Montreal, Quebec H2J 3B7, CA,
(Designated for all)
Legal Representative:
OGILVY RENAULT LLP SENCRL SRL (agent), 1981 McGill College Avenue, Suite 1600, Montreal, Quebec H3A 2Y3, CA
Patent and Priority Information (Country, Number, Date):
Patent: WO 200461458 A2-A3 20040722 (WO 0461458)
Application: WO 2003IB6416 20031215 (PCT/WO IB2003006416)
Priority Application: US 2003438012 20030103
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 52889

English Abstract
Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.

French Abstract
La presente invention se rapporte a des procedes de detection de cellules neoplasiques ou endommagees et de detection d'une resistance a de multiples medicaments dans des cellules neoplasiques ou endommagees au moyen de la detection d'un accroissement dans l'expression superficielle cellulaire d'une proteine 70 apparentee de choc thermique (HSC70) a la surface de telles cellules neoplasiques ou endommagees resistant a de multiples medicaments par comparaison au niveau d'expression de la proteine HSC70 a la surface d'une cellule normale.

4/3,AB/15 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01133517
NUCLEOPHOSMIN DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE
METHODES DIAGNOSTIQUES ET THERAPEUTIQUES PAR LA MESURE DE L'EXPRESSION DE LA NUCLEOPHOSMINE POUR DES MALADIES NEOPLASIQUES DE MULTIRESISTANCE AUX MEDICAMENTS
Patent Applicant/Assignee:
AURELIUM BIOPHARMA INC, 8475 Christophe-Colomb Avenue, Suite 1000, Montreal, Quebec City H2M 2N9, CA, CA (Residence), CA (Nationality)

Inventor(s):
GEORGES Elias, 2095 De Vouvray, Laval, Quebec H7M 3J7, US,
SERFASS Lucile, 5291 de l'Esplanade, Montreal, Quebec H2T 2Z6, CA,
BONNEAU Anne-Marie, 2095 De Vouvray, Laval, Quebec H7M 3J7, CA,
DALLAIRE Frederic, 4683 Mentana, Montreal, Quebec H2J 3B7, CA,
Legal Representative:
OGILVY RENAULT LLP S E N C R L s r l (agent), 1981 McGill College Avenue, Suite 1600, Montreal, Quebec H3A 2Y3, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200455517 A2-A3 20040701 (WO 0455517)
Application: WO 2003IB6445 20031215 (PCT/WO IB03006445)
Priority Application: US 2002433351 20021213
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 53895

English Abstract
Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a nucleophosmin (NPM) %protein% on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the nucleophosmin %protein% on the surface of a normal cell.

French Abstract
La presente invention a trait a des procedes de detection de cellules neoplasiques ou endommagees et de detection de la multiresistance aux medicaments dans des cellules neoplasiques ou endommagees par la determination d'une croissance dans l'expression en surface cellulaire d'une proteine nucleophosmine (NPM) a la surface de telles cellules neoplasiques ou endommagees a multiresistance aux medicaments par rapport a l'expression de la proteine nucleophosmine a la surface d'une cellule normale.

4/3,AB/16 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00873649
MASP-2, A COMPLEMENT-FIXING ENZYME, AND USES FOR IT
MASP-2, ENZYME DE FIXATION DE COMPLEMENTS ET SES UTILISATIONS
Patent Applicant/Inventor:
JENSENIUS Jens Christian, Finsens Alle 28, DK-5230 Odense, DK, DK (Residence), DK (Nationality)
THIEL Steffen, Nordtoftevej 11, DK-8240 Risskov, DK, DK (Residence), DK (Nationality)
Legal Representative:
HOIBERG APS (agent), St. Kongensgade 59B, DK-1264 Copenhagen K, DK,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200206460 A2-A3 20020124 (WO 0206460)
Application: WO 2001DK499 20010713 (PCT/WO DK0100499)

Priority Application: DK 20001089 20000713; DK 2001870 20010601
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AT (utility model) AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ (utility model) DE DE (utility model) DK DK (utility model) DM DZ EC EE EE (utility model) ES FI FI (utility model) GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK (utility model) SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 22913

English Abstract
The present invention relates to substantially pure mannin-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Futhermone, the present invention realates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositons comprising MASP-2 and/or MASP-2 fragments. In addition the present invetion relates to inhibitors of MASP-2 and pharmaceutical compositiosn compring such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.

French Abstract
L'invention concerne des polypeptides sensiblement purs de serine-protease-2 associee a la lectine liant le mannose (MASP-2) et leurs fragments ainsi que des acides nucleiques codant pour ces polypeptides. L'invention concerne egalement les utilisations d'un polypeptide sensiblement pur comprenant des sequences d'acides amines derives de la serine-protease-2 associee a la lectine liant le mannose (MASP-2) ou un homologue fonctionnel dudit polypeptide pour la production d'une composition pharmaceutique ainsi que des compostions pharmaceutiques comprenant MASP-2 et/ou des fragments de MASP-2. En outre, l'invention concerne des inhibiteurs de MASP-2 et des compositions pharmaceutiques comprenant ces inhibiteurs. L'invention concerne enfin des methodes permettant de detecter l'expression d'acides nucleiques de MASP-2.

4/3,AB/17 (Item 1 from file: 156)
DIALOG(R)File 156:ToxFile

232066 NLM Doc No: NTIS/01920051 Sec. Source ID: NTIS/ADA433381
52 Kilodalton %Protein% Vaccine Candidate for %Francisella% %tularensis%.

Sikora CA; Berger BJ; Cherwonogrodsky JW
DEFENCE RESEARCH AND DEVELOPMENT SUFFIELD (ALBERTA).
Source: Govt Reports Announcements & Index (GRA&I), Issue 19, 2005
Pub. Year: 2004
Order Information: 40p Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.
NTIS Prices: PC A04/MF A01

Languages: UNSPECIFIED
Record type: Completed
Technical memorandum. For identifying %Francisella% %tularensis% vaccine candidates, mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD(sub 50S) of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal dose while all the unvaccinated control mice perished. Sera were collected from these surviving mice and used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several %Francisella% %tularensis% components were identified by this noted antiserum. Mouse serum from mice vaccinated with killed F. tularensis did not identify these components. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications for some of the proteins (e.g. a %52% kilodalton (%kDa%) glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein). In low concentrations, the %52% %kDa% component caused nitrous oxide induction in tissue cultures and in high concentrations it caused cell death. Vaccination with this %protein% gave mice partial protection (20% survival) from 250 LD(sub 50) of tularemia given intranasally while the addition of other components may have acted synergistically to give enhanced protection (i.e. 100% survival).

4/3,AB/18 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent

Dialog Acc No: 10644507
IFI Chemical Acc No: 2004-0043941
Document Type: C
USE OF CROSS-PROTECTION TO IDENTIFY NOVEL VACCINE CANDIDATES FOR INFECTIOUS AGENTS; AGAINST TULAREMIA
Inventors: Berger Bradley J (CA); Cherwonogrodzky John W (CA); Sikora Christopher A (CA)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000
Probable Assignee: Her Majesty Queen CA
Attorney, Agent or Firm: NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714, US
Publication (No,Kind,Date), Applic (No,Date):
US 20040151736 A1 20040805 US 2004762241 20040123
Priority Applic(No,Date): US 2004762241 20040123
Provisional Applic(No,Date): US 60-442072 20030124

applicant

Abstract: This invention discloses methods for identifying %Francisella% %tularensis% vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted "survivor" antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a %52% %kDa% %glycoprotein%, a 45 kDa %lipoprotein% and a 19 kDa %nucleoprotein%. The %52% %kDa% component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD50s of F. tularensis LVS.

4/3,AB/19 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0348583 DBR Accession No.: 2004-20875 PATENT
New subcellular %protein% expressed from %Francisella% %tularensis% infected mammal subculture growing in synthetic salts medium of weak acidity, useful as vaccine candidate against infectious agents, e.g. bacteria, viruses, or parasites - recombinant %protein% production for use in disease therapy and vaccine

AUTHOR: SIKORA C A; BERGER B J; CHERWONOGRODZKY J W
PATENT ASSIGNEE: SIKORA C A; BERGER B J; CHERWONOGRODZKY J W 2004

PATENT NUMBER: US 20040151736 PATENT DATE: 20040805 WPI ACCESSION NO.: 2004-570708 (200455)
PRIORITY APPLIC. NO.: US 762241 APPLIC. DATE: 20040123
NATIONAL APPLIC. NO.: US 762241 APPLIC. DATE: 20040123
LANGUAGE: English

applied

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A subcellular %protein% expressed from %Francisella% %tularensis% infected mammal subculture growing in synthetic salts medium of weak acidity, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a method for expressing a subcellular %protein% from a F. tularensis infected mammal; (2) a method for identifying an infectious agent in a mammal; (3) a method for assessing in vitro the usefulness of a vaccine lot for quality assurance; and (4) a method for identifying the presence of a F. tularensis infection in a mammal. BIOTECHNOLOGY - Preferred Subcellular %Protein%: The %protein% has a molecular weight of %52% %kDa% . The infected mammal is first vaccinated with a component extracted from a first infectious agent and then infected with a high dosage of a second infectious agent. The component is O-polysaccharide, the first infectious agent is Brucella abortus and the second infectious agent is F. tularensis. The mammal is a mouse or a human. The F. tularensis infection is caused by lethal dosage of live vaccine strain. Preferred Method: Expressing a subcellular %protein% from a F. tularensis infected mammal comprises subculturing the infected mammal in synthetic salts medium of weak acidity and in sub-optimal environment to enhance the expression. The sub-optimal environment occurs during the first three rounds subculturing. The subcellular %protein% is used as a vaccine candidate against F. tularensis. Identifying an infectious agent in a mammal comprises vaccinating the mammal against a first infectious agent and subsequently exposing the mammal to a second infectious agent to be identified, thus causing the mammal to express a subcellular %protein% against the second infectious agent. The subcellular %protein% is detected from antiserum collected from the mammal. The first and second infectious agents are bacteria, fungi, yeasts, viruses, or parasites. The vaccine against the first infectious agent is O-polysaccharide. Assessing in vitro the usefulness of a vaccine lot for quality assurance comprises identifying and quantifying key subcellular %protein% in the vaccine lot. The vaccine lot is a F. tularensis vaccine lot. Identifying the presence of a F. tularensis infection in a mammal comprises detecting the presence of subcellular %protein% having a molecular weight of %52% %kDa% in the mammal's serum. Alternatively, identifying the presence of a F. tularensis infection in a mammal comprises detecting the presence of anti-myosin antibodies in the mammal's serum. ACTIVITY - Antibacterial; Fungicide; Virucide; Antiparasitic. MECHANISM OF ACTION - Vaccine. No biological data given. USE - The subcellular %protein% is useful as a vaccine candidate against the second infectious agent in a mammal, e.g. bacteria, fungi, yeasts, viruses, or parasites. It is also useful as an agent to assess the immune status and level of protection for a mammal vaccinated with the vaccine candidate. The antiserum containing the subcellular %protein% is useful for probing antigens of the infectious agent to be identified (all claimed). ADMINISTRATION - No details

given.(21 pages)

4/3,AB/20 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online

02096686 AADAAIMR03047
Identification of a vaccine candidate in %protein% extracts from %Francisella% %tularensis%
Author: Sikora, Christopher A.
Degree: M.Sc.
Year: 2004
Corporate Source/Institution: University of Lethbridge (Canada) (1112)
Source: VOLUME 44/01 of MASTERS ABSTRACTS.
PAGE 309. 97 PAGES
ISBN: 0-494-03047-X

<italic>%Francisella% %tularensis%</italic> is one of a small group of bacteria recognized for their virulence and potential for use as biological weapons. In this study we utilize a novel approach to identify an immunologically prominent component of <italic>F. tularensis</italic> that appears to be a promising vaccine candidate. <italic>Francisella</italic> is an intracellular pathogen that infects cells of the reticuloendothelial system. Other bacteria, such as <italic>Brucella</italic> spp. have this part of their life cycle in common. However, while mice injected with <italic>F. tularensis</italic> all die within three weeks of infection, mice injected with <italic>Brucella</italic> spp. survive and produce antibodies to the bacteria which are immunologically reactive not only with <italic>Brucella</italic> spp. but, also with <italic>Francisella </italic>. When we vaccinated mice with a <italic>B. abortis</italic> O-linked polysaccharide (OPS) and then challenged them with 10 LD₅₀ <italic> F. tularensis</italic> LVS, 60% survived. Sera from <italic>Brucella</italic> OPS-primed/<italic>F. tularensis</italic>-challenged mice was used to identify immune reactive proteins from <italic>F. tularensis</italic>. A novel %52% %kDa% fraction was identified. (Abstract shortened by UMI.)
?

```
  2  AU=BERGER, BRADLEY
             16  AU=BERGER, BRADLEY J
             54  AU=BERGER, BRADLEY J.
              2  AU=BERGER, BRADLEY JAMES
             18  AU=BERGER, BJ
              3  AU=BERGER, BJ*
     S13     95  E20-E23, E1, E2
? rd

>>>Duplicate detection is not supported for File 398.

>>>Duplicate detection is not supported for File 654.

>>>Duplicate detection is not supported for File 349.

>>>Duplicate detection is not supported for File 340.

>>>Duplicate detection is not supported for File 348.

>>>Duplicate detection is not supported for File 390.

>>>Duplicate detection is not supported for File 355.

>>>Duplicate detection is not supported for File 324.

>>>Duplicate detection is not supported for File 229.

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 167.

>>>Duplicate detection is not supported for File 345.

>>>Records from unsupported files will be retained in the RD set.
     S14     59  RD  (unique items)
? s s14 and tularensis
             59  S14
          15492  TULARENSIS
     S15      1  S14 AND TULARENSIS
? t s15/3,ab/1
>>>No matching display code(s) found in file(s): 65, 135, 167, 180, 229,
   345, 355, 390, 398

 15/3,AB/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

  141156100    CA: 141(10)156100y    PATENT
  Mammals immunizing sequentially with different infectious agents and
  observing cross-protection to identify novel vaccine candidates
  INVENTOR(AUTHOR): Sikora, Christopher A.; Berger, Bradley J.;
Cherwonogrodzky, John W.
  LOCATION: Can.,
  PATENT: U.S. Pat. Appl. Publ. ; US 20040151736 A1  DATE: 20040805
  APPLICATION: US 762241 (20040123) *US PV442072 (20030124)
  PAGES: 21 pp.  CODEN: USXXCO  LANGUAGE: English
  PATENT CLASSIFICATIONS:
    CLASS:  424190100; A61K-039/02A
? s s14 and francisella
             59  S14
          15695  FRANCISELLA
     S16      1  S14 AND FRANCISELLA
? t s16/3,ab/1
>>>No matching display code(s) found in file(s): 65, 135, 167, 180, 229,
```

345, 355, 390, 398

16/3,AB/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

141156100 CA: 141(10)156100y PATENT
Mammals immunizing sequentially with different infectious agents and observing cross-protection to identify novel vaccine candidates
INVENTOR(AUTHOR): Sikora, Christopher A.; Berger, Bradley J.; Cherwonogrodzky, John W.
LOCATION: Can.,
PATENT: U.S. Pat. Appl. Publ. ; US 20040151736 A1 DATE: 20040805
APPLICATION: US 762241 (20040123) *US PV442072 (20030124)
PAGES: 21 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424190100; A61K-039/02A
?

```
ef    Items  Index-term
E1        3 *AU=SIKORA, C
E2       11  AU=SIKORA, C.
E3        4  AU=SIKORA, C. A.
E4        2  AU=SIKORA, C. R.
E5        3  AU=SIKORA, C.A.
E6        1  AU=SIKORA, C.W.
E7        2  AU=SIKORA, CA
E8        1  AU=SIKORA, CAROL
E9        2  AU=SIKORA, CHRISTINE
E10       5  AU=SIKORA, CHRISTINE A.
E11       2  AU=SIKORA, CHRISTOPHER A.
E12       2  AU=SIKORA, CLAUDIA

          Enter P or PAGE for more
? s e1-e3, e5, e7, or e11
>>>Operator "OR" in invalid position
? s e1-e3, e5, e7, e11
>>>One or more prefixes are unsupported
>>>  or undefined in one or more files.
               3  AU=SIKORA, C
              11  AU=SIKORA, C.
               4  AU=SIKORA, C. A.
               3  AU=SIKORA, C.A.
               2  AU=SIKORA, CA
               2  AU=SIKORA, CHRISTOPHER A.
      S6      25  E1-E3, E5, E7, E11
```

12/3,AB/3 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0006996712 BIOSIS NO.: 199039050101
PATHOGENICITY OF THE FRANCISELLA-%TULARENSIS% LIVE VACCINE STRAIN LVS
AUTHOR: %CHERWONOGRODZKY J W% (Reprint); DI NINNO V L; KNODEL M H; SPENCE M R
AUTHOR ADDRESS: DEFENCE RES ESTABLISHMENT SUFFIELD, BOX 4000, MEDICINE HAT, ALBERTA T1A 8K6**CANADA
JOURNAL: Abstracts of the Annual Meeting of the American Society for Microbiology 90 p124 1990
CONFERENCE/MEETING: 90TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY 1990, ANAHEIM, CALIFORNIA, USA, MAY 13-17, 1990. ABSTR ANNU MEET AM SOC MICROBIOL.
ISSN: 0094-8519
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

```
undefined in one or more files.
               1  AU=CHERWONOGRODZKY, JW*
              52  AU=CHERWONOGRODZKY, J. W.
              22  AU=CHERWONOGRODZKY, J.W.
               1  AU=CHERWONOGRODZKY, JOHN
               8  AU=CHERWONOGRODZKY, JOHN W
              23  AU=CHERWONOGRODZKY, JOHN W.
               2  AU=CHERWONOGRODZKY, JOHN WALTER
              19  AU=CHERWONOGRODZKY, JW
              20  AU=CHERWONOGRODZKY J.W.
               7  AU=CHERWONOGRODZKY JOHN
              41  AU=CHERWONOGRODZKY JOHN W
              56  AU=CHERWONOGRODZKY JW
               1  AU=CHERWONOGRODSKY, J. W.
              25  AU=CHERWONOGRODZKY
              13  AU=CHERWONOGRODZKY J
              77  AU=CHERWONOGRODZKY J W
      S8     341  E25, E16, E18, E20-E24, E8, E10-E12, E2-E4, E6
? s s8 and tularensis
             341  S8
           15492  TULARENSIS
      S9      44  S8 AND TULARENSIS
? s s9 and fransicella
              44  S9
              16  FRANSICELLA
     S10       0  S9 AND FRANSICELLA
```